Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
Trial details
- Registry ID
- NCT07095465
- Drugs studied
- ACP-204
TrialRedline tracks 19 clinical trials sponsored by ACADIA Pharmaceuticals Inc.: 11 Phase 3, 4 Phase 2 / 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673 | ACP-204 | Recruiting | 2028-01Estimated |
| Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum DisorderNCT05523895 | Pimavanserin | Completed | 2024-09-27Actual |
| Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum DisorderNCT05555615 | Pimavanserin | Terminated | 2025-02-14Actual |
| An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeNCT04988867 | Trofinetide | Terminated | 2023-05-31Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisNCT07029581 | ACP-204 | Recruiting | 2028-02Estimated |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseNCT07284667 | ACP-211 | Recruiting | 2027-08Estimated |
| ACP-104 in Acutely Psychotic Subjects With SchizophreniaNCT00490516 | ACP-104 | Completed | 2008-02Actual |
| Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the KneeNCT05008835 | ACP-044 Dose A, ACP-044 Dose B | Terminated | 2022-10-06Actual |
Names as written in the registry records.
NCT06173531 · ACADIA Pharmaceuticals Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score Description: The HQ-CT is a nine-item questionnaire designed to be completed by caregivers of subjects with PWS. It is a revision of the 11-item HPWSQ-R and has been further validated. The Foundation for Prader-Willi Research has made the HQ-CT available for clinical studies in PWS, and it is the consensus instrument within the PWS research community for measuring observable behaviors that stem from subjects' excessive drive to eat. The HQ-CT should be completed by the same caregiver throughout the study. The HQ-CT will be administered to the caregiver by a rater using standardized prompts. The Food Safe Zone should be administered immediately before administration of the HQ-CT. A higher score on the HQ-CT indicates greater severity of hyperphagia. Time frame: Baseline to Week 12. After: Measure: Change From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score Description: The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. The questionnaire is administered to the caregiver by a trained rater using standardized prompts, and the same caregiver is expected to complete the assessment throughout the study whenever possible. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 36, with higher scores indicating greater severity of hyperphagia. A decrease from baseline reflects improvement, and a reduction of 7.7 points has been identified as a clinically meaningful within-participant improvement. Time frame: Baseline to Week 12.
Before: Estimated. After: Actual.
Before: 170 participants (planned). After: 175 participants (actual).
Before: Estimated. After: Actual.
Before: Oct 2025. After: 19 Aug 2025.
Before: Active not recruiting. After: Completed.
NCT07095465 · ACADIA Pharmaceuticals Inc.
Before: Enrolling by invitation. After: Recruiting.
NCT06420297 · ACADIA Pharmaceuticals Inc.
Before: Estimated. After: Actual.
Before: 160 participants (planned). After: 168 participants (actual).
Before: Estimated. After: Actual.
Before: May 2029. After: 19 Dec 2025.
Before: Enrolling by invitation. After: Terminated.
NCT07284667 · ACADIA Pharmaceuticals Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 28. After: Measure: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 28.
NCT07095465 · ACADIA Pharmaceuticals Inc.
Before: Not yet recruiting. After: Enrolling by invitation.